Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer (Q37097424)

18 August 2017

1 reference

title

Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer (English)

1 reference

18 August 2017

1

Johan Bussink

1 reference

18 August 2017

Albert J van der Kogel

series ordinal

2

1 reference

PubMed ID

18308254

18 August 2017

Johannes H A M Kaanders

series ordinal

3

1 reference

18 August 2017

1 March 2008

1 reference

Lancet Oncology Commission

18 August 2017

1 reference

18 August 2017

9

1 reference

18 August 2017

3

1 reference

18 August 2017

288-296

1 reference

Stress and radiation-induced activation of multiple intracellular signaling pathways

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Clinical studies of hypoxia modification in radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Severe cutaneous reaction during radiation therapy with concurrent cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

PTEN enters the nuclear age.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

PIK3CA mutations in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

The phosphoinositide 3-kinase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Cellular survival: a play in three Akts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

The PI3K-PDK1 connection: more than just a road to PKB

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

AKT can be activated in the nucleus.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

The role of double-strand break repair — insights from human genetics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Essential role for nuclear PTEN in maintaining chromosomal integrity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Mechanism and regulation of human non-homologous DNA end-joining

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Epidermal growth factor receptor and DNA double strand break repair: the cell's self-defence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

The hazard of accelerated tumor clonogen repopulation during radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Hypoxia--a key regulatory factor in tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

ER stress, hypoxia tolerance and tumor progression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

HIF-1: mediator of physiological and pathophysiological responses to hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Transcriptional response to hypoxia in human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fr

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Hypoxia-inducible factor-1alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Radiation combined with EGFR signal inhibitors: head and neck cancer focus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Prognostic Value of an Activation State Marker for Epidermal Growth Factor Receptor in Tissue Microarrays of Head and Neck Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Akt activation correlates with adverse outcome in tongue cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Prognostic value of activated Akt expression in oral squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970073-1

7 January 2021

10.1016/S1470-2045(08)70073-1

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18308254